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ABSTRACT 
BACKGROUND: The frequency of upper gastrointestinal (GI) tract involvement in Crohn`s disease 
(CD) has been reported with a large variation. Risk factors and disease course of patients with upper
GI tract involvement remain largely elusive. 
METHODS: Data on CD patients in the Swiss Inflammatory Bowel Disease Cohort were analyzed. 
Patients with upper GI tract involvement were compared to controls. Logistic regression models for 
prediction of upper GI tract involvement and Cox proportional hazard models for occurrence of 
complications were computed. 
RESULTS: We included 1638 CD patients, of whom 107 (6.5%) presented with upper GI tract 
involvement at the time of diagnosis and 214 (13.1%) at any time. Prevalence of such involvement at 
diagnosis increased over time (5.1% for 1955-1995 vs. 11.3% for 2009-2016). In a multivariate logistic 
regression model, male sex and diagnosis between 2009-2016 (vs. before 1995) were independent 
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predictors for presence of upper GI tract involvement at CD diagnosis (OR 1.600, p=0.021 and OR 
2.686, p<0.001), while adult age was a negative predictor (OR 0.388, p=0.001). Patients with upper GI 
tract involvement showed a disease course similar to control patients (HR for any complications 
0.887 [95% CI 0.409-1.920]), and a trend towards occurrence of fewer intestinal fistulas (log-rank test 
p=0.054).  
CONCLUSIONS: Prevalence of upper GI tract involvement has been increasing over the past decades. 
Male sex and young age at diagnosis were identified as the main predictive factors for such 
involvement at CD diagnosis. Involvement of upper GI tract did not result in a worse outcome.  
Key words: Inflammatory bowel disease; natural history; upper gastrointestinal tract; Crohn’s 
disease; esophagus; stomach; duodenum; jejunum. 
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INTRODUCTION 
Crohn’s disease (CD) is a chronic disorder of the gastrointestinal (GI) tract that leads to 
development of bowel damage and impaired gut function.1,2 Although CD most frequently affects the 
ileocecum, it may involve any portion of the GI tract, from the oral cavity to the anus. Upper GI tract 
involvement refers to the affection of esophagus, stomach, duodenum and jejunum, which may 
occur either isolated (Montreal Classification L4) or together with other CD locations (L1-3).3 Typical 
CD-related endoscopic lesions of the esophagus consist of aphthae, erosions and ulcers (not related
to gastro-esophageal reflux disease).4-8 For gastroduodenal CD, endoscopic findings include apthae, 
longitudinal/irregular erosions, ulcers, and bamboo-like appearances.9-12  
The frequency of endoscopic lesions in the upper GI tract has been reported with a large 
variation. Early studies documented a low prevalence between 0.5-4% of CD patients.13-15 However, 
more recently reported rates have been much higher ranging from 30 to 75%.16,17 Horjus and 
colleagues systematically assessed newly diagnosed CD patients and observed endoscopic lesions in 
the upper GI tract in 60 out of 108 examined patients (55%).18 These discrepancies regarding 
prevalence rates of upper GI tract lesions are probably related to i) non-uniform definitions of CD-
related lesions, ii) the use of different diagnostic modalities (radiologic exams in early studies vs. 
endoscopies in later investigations), iii) differences in the examined patient populations (newly 
diagnosed patients versus treated patients), and iv) differences regarding the frequency of upper 
endoscopy as an initial diagnostic proce ure. Current ECCO guidelines recommend – irrespective of 
the findings at ileo-colonoscopy – further investigations (including upper endoscopy) to assess 
location and extent of any CD in the upper GI tract.1 In clinical practice – however – such 
investigation for mapping disease extent is not regularly performed at CD diagnosis except for 
symptoms that are suggestive for upper GI tract involvement.19 This is mostly attributed to the fact, 
that the evidence level for this particular ECCO recommendation is weak (evidence level 5, expert 
opinion) and the grade of recommendation is low (D).20  
Previous studies on upper GI tract involvement have been limited by the small number of 
patients or by a cross-sectional study design.21-23 As of yet, the frequency of upper GI tract 
involvement, its risk factors and its impact on future disease course have not been systematically 
assessed in a large, nation-wide IBD cohort from a cross-sectional and longitudinal perspective. It 
remains further unknown whether the increasing use of upper endoscopies and anti-TNF treatment 
have changed the landscape and outcome of upper GI tract involvement. Given this current lack of 
knowledge, we launched this study using data from the nation-wide Swiss Inflammatory Bowel 
Disease Cohort Study (SIBDCS) to answer the following questions: 1) What is the prevalence of upper 
GI tract involvement in the SIBDCS? 2) What are associated risk factors that predict such 
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involvement? And 3) Is involvement of the upper GI tract associated with a complicated disease 
outcome?  
METHODS 
Study design 
In this large, observational study, we retrospectively analyzed prospectively obtained data 
from the SIBDCS. The SIBDCS started enrolment of IBD patients in 2006 and includes patients from all 
regions across Switzerland. All patients were diagnosed with IBD according to international 
guidelines. The SIBDCS is funded by the Swiss National Science Foundation and has been approved by 
the local ethics committee of each participating center (institutional review board approval No. EK-
1316, approved on February 5, 2007). All patients had provided written informed consent prior to 
inclusion into the SIBDCS.  
Study population and data collection 
Inclusion criteria for the SIBDCS have been published elsewhere.24 A thorough clinical and 
laboratory assessment is performed at the time of inclusion into the study. Patients enrolled in the 
SIBDCS attend follow-up visits at least once a year. Detailed questionnaires are completed by the 
patients and the responsible physicians at enrolment and at each follow-up visit. These 
questionnaires capture clinical, socioeconomic and psychosocial data. These data are collected and 
validated by the data center of the SIBDCS, which follows rigorous rules to ensure data quality. For 
the purpose of this study, the following inclusion criteria were applied: i) diagnosis of CD, ii) 
enrolment into the SIBDCS between 2006 and 2016, and iii) detailed documentation of disease 
location at the time of diagnosis and during follow-up. The questionnaire used in the SIBDCS assesses 
current disease location as follows (see Supplementary Figure 1): esophagus/stomach (segment A), 
duodenum/jejunum (segment B), ileum (segment C), cecum (segment D), ascending colon (segment 
E), transverse colon (segment F), descending colon (segment G), sigmoid (segment H), rectum 
(segment I), and anus (segment J). In addition, disease location is classified into i) upper 
gastrointestinal tract, ii) ileal disease only, iii) ileo-colonic disease, and iv) colonic disease only. The 
SIBDCS questionnaire further assesses disease location at CD diagnosis using the Montreal 
classification (see definitions). Diagnostic modalities for assessment of disease location are reported 
and consist of: i) radiological studies, ii) endoscopic studies, and iii) surgery. In case of diagnosis 
before 2006, data on upper GI tract involvement was retrospectively assessed. For the purpose of 
this study, patients were excluded if no initial assessment of disease location was available. 
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Outcome measures and definitions 
The following outcome parameters were assessed as possible predictors for the presence of 
upper GI tract involvement at diagnosis and at any time during the follow-up: gender (females vs. 
male), age at diagnosis (≤16years vs. >16 years), length of diagnostic delay (continuous variable), 
smoking at CD diagnosis (yes vs. no), current smoking (yes vs. no), positive family history for CD (at 
least one first-degree relative with CD; yes vs. no), presence of extra-intestinal manifestations during 
disease course (yes vs. no), disease duration (continuous variable), and perianal fistulizing disease 
(yes vs. no).  
In order to assess whether or not upper GI tract involvement affects disease outcome, the 
following surrogate markers for a complicated disease course were assessed: presence of bowel 
strictures, presence of intestinal and perianal fistulas, and need for CD-related intestinal surgery. 
Patients presenting with at least one of these complications or undergoing at least one type of CD-
related intestinal surgery were summarized as having “any complication”. Intestinal surgery was 
defined as any of the following intervention: surgery for fistula or abscess, ileal resection, ileo-cecal 
resection, small bowel resection other than terminal ileum, right or left colectomy, colectomy, 
proctocolectomy, ileostomy, and colostomy.  
Disease location was classified according to the Montreal classification.3 For CD, L1 denotes 
disease in the terminal ileum, L2 denotes disease in the colon, L3 denotes ileocolonic disease, and L4 
denotes disease in the upper gastrointestinal tract. For the purposes of this study, upper GI tract 
involvement was defined as follows: i) involvement of esophagus or stomach, or ii) involvement of 
duodenum or jejunum (Supplementary Figure 1), based on available diagnostic modalities 
(endoscopy, radiology, or surgery). Disease duration was defined as the time between CD diagnosis 
and the beginning of the last available follow-up period. Current age was defined as age at the 
beginning of the last available follow-up period, while current smoking status referred to the smoking 
status at the beginning of the last available follow-up period. Diagnostic delay was defined as the 
time interval from onset of CD-related symptoms, until CD diagnosis was established.25 
Statistical analysis 
All statistical analyses were performed with the statistical package program STATA (version 13.1, 
College Station, Texas, USA). Data distribution was analyzed using Normal-QQ-Plots. Quantitative 
data are presented as either mean ± standard deviation (SD) in case of normal distribution or median 
and interquartile range (IQR) (for non-normally distributed data). Categorical data are summarized as 
the percentage of the group total. Differences in distributions of quantitative data were assessed by 
the Student’s t-test (for normally distributed data) and by the Wilcoxon rank-sum test in case of non-
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normally distributed data. Comparison between categorical data was performed using the chi-square 
test or the exact Fisher’s test in case of small sample size (n<10). Stepwise logistic regression 
modeling was performed in order to evaluate the association between potential risk factors and 
upper GI tract involvement (=dependent variable). In a first step, the potential risk factors were 
tested separately (in a univariate model). In a second step, all risk factors with a p-value <0.1 in the 
univariate analysis were entered together into the multivariate logistic regression model. Kaplan-
Meier estimates were used to compute the cumulative incidence of complications stratified by upper 
GI tract involvement (yes vs. no). The log-rank test was used to detect overall statistical difference in 
estimates. Cox proportional hazard analysis was used to examine the association of upper GI tract 
involvement with occurrence of complications. Patients were censored at the time, when first 
complication occurred, or December 31, 2016. For the purpose of this study, a p-value of <0.05 was 
considered statistically significant.  
RESULTS 
Patient demographics 
Of the 1840 CD patients enrolled in the SIBDCS at the time of analysis, we included a total of 1638 CD 
patients. 202 patients were excluded due to unknown disease location. Median age at diagnosis was 
26 years (IQR 20-37) with a median diagnostic delay of 5 months (IQR 1-24), 46.8% were males. 
Median follow-up of these patients (enrolment to last visit) was 5 years (IQR 2-8 years, range 0-11 
years). Patient demographic and disease characteristics are shown in Supplementary Table 1. The 
following diagnostic modalities were used to diagnose upper GI tract involvement at CD diagnosis 
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and during follow-up: 1) radiology 2.8 and 7.5%, 2) endoscopy 97.2% and 90%, and 3) surgery 0 and 
2.5%.  
Upper gastrointestinal tract involvement at CD diagnosis 
We identified 107 patients with upper GI tract involvement at the time of CD diagnosis 
corresponding to 6.5% of the studied CD cohort. Compared to controls with CD without upper GI 
tract involvement, these patients were more often males (57.9 vs. 46.1%, p=0.017), younger at 
diagnosis (median 24 vs. 27 years, p=0.027) and showed a trend towards a longer diagnostic delay 
(median 7 vs. 5 years, p=0.058). For details see Table 1. Frequency of upper GI tract involvement at 
the time of CD diagnosis was increasing over time. While such involvement was seen in 5.1% of the 
patients diagnosed between 1955 and 1995, the prevalence of upper GI tract involvement was 11.3% 
for patients diagnosed between 2009 and 2016 (p=0.001, Figure 1). Most of the patients did not 
show exclusive upper GI tract involvement as first manifestation of CD. They rather presented with 
ileocecal CD (56.1%) followed by ileal (16.8%) and colonic CD (14.0%). Frequency of ileal (16.8 vs. 
27.6%, p=0.015) and colonic CD (14.0 vs. 22.9%, p=0.034) was lower compared to control patients. 
Upper gastrointestinal tract involvement at any time 
In a total of 214 patients, upper GI tract involvement was identified at any time of the follow-up 
(13.1%). Patients with upper GI tract involvement at any time were more often males  (57.0 vs. 45.3, 
p=0.001) and were younger at diagnosis (median 25 vs. 27 years, p=0.011). They more often suffered 
from Erythema nodosum (11.7 vs. 6.7%, p=0.009) and aphthous ulcers (20.1 vs. 12.2%, p=0.002), and 
were more likely to be treated with anti-TNF (72.9 vs. 60.5%, p=0.001), but less likely with 5-ASA 
(48.6 vs. 58.5%, p=0.006) compared to CD controls (Table 2). Compared to controls, patients with 
upper GI tract involvement were less likely to have colonic CD, both at CD diagnosis (16.4 vs. 23.2%, 
p=0.025) and at latest follow-up (18.1 vs. 35.7%, p<0.001, Figure 2).  
Predictive factors associated with upper gastrointestinal tract involvement 
In a multivariate logistic regression model, male sex and diagnosis between 2009 and 2016 
(compared to a diagnosis before 1995) were identified as independent predictive factors for the 
presence of upper GI tract involvement at the time of CD diagnosis (OR 1.600, p=0.021, and OR 
2.686, p<0.001), while adult age at diagnosis (>16 years) was a negative predictor (OR 0.388, 
p=0.001, Table 3). Male sex (OR 1.779, p<0.001), presence of Erythema nodosum (OR 1.793, 
p=0.019), apthous ulcers (OR 1.838, p=0.002), and anti-TNF treatment (OR 1.534, p=0.010) were 
associated with the presence of upper GI tract involvement at any time, while longer disease 
duration and adult age at diagnosis (>16 years) were negative predictors (OR 0.981 per year, 
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p=0.016, and OR 0.585, p=0.014, Table 4).  
Impact of upper gastrointestinal tract involvement on CD complications and intestinal surgery 
To investigate the impact of upper GI tract involvement on disease course, we analyzed the follow-up 
of all patients with upper GI tract involvement at the time of CD diagnosis and compared them to 
controls without such involvement. During a median follow-up of 5 years (IQR 2-8 years), we 
identified 1049 cases with occurrence of complications (=composite of intestinal stenosis, perianal 
fistula, intestinal fistula, any fistula, intestinal resection surgery, and surgery for abscess or fistula): 
60 cases were detected in the group of patients with upper GI tract involvement at the time of CD 
diagnosis (56.1%), while 989 cases were observed in the control group (64.6%). Follow-up time of 
patients with upper GI tract involvement was comparable to that of patients without such 
involvement (median 4 years, IQR 2-8 years vs. 5 years, IQR 2-8 years, n.s.). Kaplan Meier curves for 
complication-free survival are depicted in Figure 3. There was no significant difference detected 
between patients with upper GI tract involvement versus patients without such involvement (median 
time until any complications 6.17 (95% CI 5.67-7.41) vs. 6.42 years (95% CI 5.00-13.01), logrank test 
p=0.341). Kaplan Meier analysis for internal-fistula free survival showed a trend towards significance 
with a better outcome in patients with upper GI involvement at the time of CD diagnosis (logrank test 
p=0.054), other examined complications did not show any differences between the two groups 
(Figure 3 and Supplementary Figure 2). Hazard ratios for development of complications are 
summarized in Table 5. Again, no significant differences were seen between patients with upper GI 
tract involvement compared to controls. Subgroup analyses stratified by demographics and risk 
factors for occurrence of complications did not show any significant effect modification 
(Supplementary Table 2). To further dissect specific locations of L4 phenotype, patients with 
involvement of esophagus/stomach (Segment A, Supplementary Figure 1) and patients with 
involvement of duodenum/jejunum (Segment B) were analyzed separately and compared to non-L4 
patients with regards to development of future complications. Since data on Segment A vs. B 
involvement was available from first follow-up visit on only, first follow-up visit was considered 
baseline evaluation to compute Kaplan Meier curves. No differences were seen between Segment A 
and B involvement compared to non-L4 involvement in terms of development of stenosis, 
development of fistula and occurrence of any complications (Supplementary Figure 3). Patients with 
esophageal/stomach involvement showed even a trend towards less complications and fistula 
development. However, patients with duodenal/jejunal involvement were more likely to undergo 
intestinal resection in the follow-up compared to non-L4 patients.  
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DISCUSSION 
Although CD most often affects the ileocecum, CD may actually involve any part of the GI 
tract. Frequency of upper GI tract involvement has been reported with a large variation. Up to date 
and in the era of increasing use of upper endoscopies and early-TNF treatment, prevalence rates in a 
large, nation-wide IBD cohort are unknown, and possible risk factors for and the impact of upper GI 
involvement on future disease course remain largely elusive. We therefore investigated in a large 
cohort of CD patients 1) the frequency of upper GI tract involvement at diagnosis and at any time 
during follow-up; 2) predictive factors associated with the presence of such involvement; and 3) the 
disease outcome in patients with upper GI tract involvement compared to controls.  
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Upper GI tract involvement was observed in 6.5% of the patients at the time of CD diagnosis 
and in 13.1% of the patients at any time during the follow-up. Of note, these rates were increasing 
over time with 5.1% of the patients showing upper GI involvement at CD diagnosis before 1995, 
while 11.3% of the patients that were diagnosed between 2009 and 2016 had such involvement. The 
rates reported in our study are considerably lower than those of recent articles including a 
comprehensive analysis of the NIDDK IBD Genetics Consortium database (16.4%).23 They rather 
mirror prevalence rates of earlier studies. 13-15 This is most probably due to the fact that upper 
endoscopy is not regularly performed at the time of CD diagnosis, if symptoms are not suggestive for 
upper GI tract involvement. However, increasing rates over the past few decades with the highest 
frequency within the past few years go in line with the ECCO guidelines, which actually recommend – 
although with very low evidence – such an approach.1 It has yet to be determined whether the 
difference between rates at diagnosis vs. at any time during the follow-up is due to progressing 
disease or due to the increasing use of upper endoscopy over time.  
Male sex, young age at diagnosis (≤16 years), and a diagnosis after 2009 (compared to before 
1995) were the only factors associated with the presence of upper GI tract involvement at CD 
diagnosis. This is in accordance with a previous publication by Lazarev and colleagues who 
demonstrated a higher rate of male patients suffering from L4 compared to non-L4 disease (53 vs. 
47%, p=0.02).23 Our multivariate logistic regression model makes this data more robust. The 
identification of the time point of diagnosis as a predictive factor may be largely attributed to the 
increasing use of upper endoscopy over time regardless of initial symptoms as suggested by the 
current ECCO guidelines.1 Of note, no other predictive factors were identified in this logistic 
regression analysis. Neither BMI, family history, smoking status nor diagnostic delay was able to 
predict upper GI tract involvement at the time of CD diagnosis. However, anti-TNF treatment, and 
presence of Erythema nodosum and oral ulcers were positively associated with upper GI tract 
involvement at any time, while disease duration was negatively associated. The effect of anti-TNF 
treatment has to be interpreted cautiously; it is actually more likely, that patients with upper GI tract 
involvement have a higher chance of being treated with biologics given previous data suggesting 
higher complication rates in these patients, although the latter was not confirmed in our study. The 
retrospective nature of the analysis does not make it possible to disentangle this relationship. 
Disease course of patients with upper GI tract involvement at the time of CD diagnosis does 
not appear to be significantly different from that of control CD patients. Moreover, patients with 
upper GI tract involvement seem to show an even better outcome regarding development of 
intestinal fistulas, which was particularly observed in patients with esophageal/stomach involvement. 
Even a subgroup analysis for patients with duodenal/jejunal involvement revealed an outcome 
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similar to that of non-upper GI tract patients, except for higher rates of intestinal resection. This 
contrasts previous findings, which suggested higher rates of complications in L4 patients. It has been 
previously shown that L4 phenotype is associated with structuring disease and abdominal surgery 
(compared to non-L4 CD).23 There are two possible explanations for our results: 1) upper GI tract 
involvement is indeed no risk factor for a complicated disease outcome. This is supported by a Cox 
regression model stratified by demographics and multiple risk factors without any significant 
modifying effect on disease outcome in patients with upper GI tract involvement. 2) Increased 
detection of patients with upper GI tract involvement at the time of diagnosis due to increased use of 
upper endoscopy over time may have resulted in over-diagnosis of such involvement considering 
even minor and particularly asymptomatic involvement as significant. Therefore, its potentially 
negative effect on disease course may have been vanished. Either or our data question the current 
guidelines, which recommend – based on expert opinion only – upper endoscopy regardless of 
symptoms.1 One might argue that increased use of anti-TNF in patients with upper GI tract 
involvement has resulted in a favourable outcome. However, even after correcting for anti-TNF 
treatment, outcome of patients with vs. without such involvement appears to be the same. In 
patients never treated with anti-TNF, there was even a trend towards a better outcome with upper 
GI tract involvement at the time of CD diagnosis. Prospective trials are needed in order to investigate, 
whether or not upper endoscopy and early identification of upper GI tract involvement has its value. 
Our study has several strengths and limitations. We analyzed a large number of patients 
(>1600) in a nation-wide IBD cohort. Stringent inclusion and exclusion criteria, close follow-up, and 
standardized enrolment and follow-up questionnaires completed by both patients and physicians 
minimized the drawback of a retrospective data analysis. In addition, disease location is reported in 
detail in the Swiss IBD cohort, both at enrolment and during follow-up. In most of the patients 
(>90%), disease location was assessed by endoscopy, although the SIBDCS questionnaire did not 
capture the number of upper vs. lower endoscopies for assessment of disease location. A median 
follow-up of 5 years makes the outcome analysis of patients with upper GI tract involvement at the 
time of CD diagnosis vs. controls more reliable. However, there might be a possible selection bias 
given the fact that the SIBDCS is not population based. Patients with more severe course (recruited at 
tertiary referral centers) might be overrepresented. Thus, our findings cannot be applied one to one 
to a general IBD population. It cannot be ruled out that some non-specific endoscopic changes due to 
NSAR intake or H. pylori infection were misinterpreted as CD manifestations, therefore the frequency 
of upper GI tract involvement might have been overestimated. Due to the nature of our study and 
the reliance on retrospective questionnaires, independent verification of physician`s findings was not 
feasible. Given the fact that these data are not independent, it was not possible to determine 
direction of the association between anti-TNF treatment and upper GI tract involvement. A clear 
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limitation is that our questionnaire does not distinguish between duodenal and jejunal disease. 
Therefore, a separate analysis for jejunal upper GI tract involvement vs. non-jejunal upper GI tract 
involvement was not feasible, although jejunal disease has been previously identified as a risk factor 
for CD complications.23 Very lately, both L4 jejunal and L4 proximal ileal disease were associated with 
higher rates of intestinal resection.26 At least, we were able to perform subgroup analysis for 
esophageal/stomach and duodenal/jejunal involvement. While the latter group was more likely to 
undergo intestinal resection in the follow-up, there were otherwise no differences in terms of 
development of future complications in both groups compared to non-L4 patients. We defined 
severe disease course as development of complications in the follow-up only, which is a rather hard 
outcome. There might be differences between non-L4 and L4 regarding softer outcomes such as seen 
for Erythema nodosum, which was associated with upper GI tract involvement in the follow-up. 
However, we did not include extraintestinal manifestations in our definition of severe disease. 
In conclusion, upper GI tract involvement is frequently observed and prevalence has been 
increasing over the past decades, most probably due to an increasing use of screening upper 
endoscopies. Male sex and young age ≤16 years were identified as the main predictive factors for 
upper GI tract involvement at the time of CD diagnosis. Even after correcting for anti-TNF treatment, 
patients with upper GI tract involvement at CD diagnosis did not show a worse outcome compared to 
controls. This questions the current recommendation for screening by upper endoscopy at the time 
of CD diagnosis regardless of symptoms. Prospective trials are needed evaluating the value of such 
early upper endoscopy.  
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WHAT IS KNOWN? 
- Frequency of upper gastrointestinal (GI) tract involvement in Crohn`s disease (CD) has been
reported with a large variation.
- Risk factors and disease course of patients with upper GI tract involvement remain elusive.
- Current guidelines recommend screening for upper GI tract involvement at the time of CD
diagnosis regardless of symptoms, although evidence level is low.
WHAT IS NEW? 
- Upper GI tract involvement was observed in 6.5% of patients at the time of CD diagnosis and
in 13.1% of patients at any time during the follow-up.
- Frequency of upper GI tract involvement at diagnosis was increasing over time with the
highest rates between 2009 and 2016.
- Male sex, young age ≤16 years and a diagnosis between 2009 and 2016 were identified as
predictive factors for upper GI tract involvement at the time of CD diagnosis.
- Patients with upper GI tract involvement did not show a worse outcome compared to
controls, questioning the role of upper endoscopy at CD diagnosis in all patients regardless of
symptoms.
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TABLES 
Table 1 
No Upper GI involvement at 
diagnosis 
Upper GI involvement 
at diagnosis 
p-value
Number of patients 1531 107 
Sex 
  Male 
  Female 
705 (46.1) 
826 (53.9) 
62 (57.9) 
45 (42.1) 0.017 
Age at diagnosis [years] 
(median, IQR, range) 
27, 20-37 
1-81
24, 18-35 
11-74 0.027 
Age at diagnosis 
  16 or less 
  More than 16 
143 (9.4) 
1387 (90.7) 
19 (17.8) 
88 (82.2) 0.005 
Year of diagnosis 
  1955-1995 
  1996-2003 
  2004-2008 
  2009-2016 
431 (28.2) 
380 (24.8) 
396 (25.9) 
323 (21.1) 
23 (21.5) 
17 (15.9) 
26 (24.3) 
41 (38.3) <0.001 
Diagnostic delay [months] 
(median, IQR, range) 
5, 1-23 
0-404
7, 2-32 
0-531 0.058 
BMI [kg/m
2
] 
(median, IQR, range) 
24, 21-27 
13-49
23, 21-26 
15-46 0.383 
Other disease location at 
diagnosis 
  L1 
  L2 
  L3 
  No other location 
423 (27.6) 
350 (22.9) 
758 (49.5) 
- 
18 (16.8) 
15 (14.0) 
60 (56.1) 
14 (13.1) 
0.019 
Smoking status at diagnosis 
  Non-Smoker 
  Smoker 
755 (51.3) 
718 (48.7) 
54 (52.9) 
48 (47.1) 0.742 
NSAID intake at CD onset 
  No 
  Yes 
1000 (82.6) 
210 (17.4) 
76 (84.4) 
14 (15.6) 0.663 
Family history of IBD 
  No 
  Yes 
1166 (84.6) 
212 (15.4) 
84 (87.5) 
12 (12.5) 0.447 
Table 1: Patient demographic and disease characteristics of CD patients with upper GI tract 
involvement at diagnosis versus control CD patients without such involvement of the proximal GI 
tract. 
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Table 2 
No Upper GI involvement at 
any time during disease 
history 
Upper GI involvement 
any time during  
disease history 
p-value
Number of patients 1424 214 
Sex 
  Male 
  Female 
645 (45.3) 
779 (54.7) 
122 (57.0) 
92 (43.0) 0.001 
Age at diagnosis [years] 
(median, IQR, range) 
27, 20-37 
1-81
25, 19-34 
5-74 0.011 
Age at diagnosis 
  16 or less 
  More than 16 
129 (9.1) 
1294 (90.9) 
33 (15.4) 
181 (84.6) 0.004 
Year of diagnosis 
  1955-1995 
  1996-2003 
  2004-2008 
  2009-2016 
406 (28.5) 
354 (24.9) 
361 (25.4) 
302 (21.2) 
48 (22.4) 
43 (20.1) 
61 (28.5) 
62 (29.0) 0.019 
Diagnostic delay [months] 
(median, IQR, range) 
5, 123 
0-404
6, 1-24 
0-530 0.501 
Age [years] 
(median, IQR, range) 
44, 33-56 
16-94
37, 29-51 
17-81 <0.001 
Disease duration [years] 
(median, IQR, range) 
12, 7-21 
0-57
10, 6-19 
0-52 0.009 
BMI [kg/m
2
] 
(median, IQR, range) 
24, 21-27 
13-49
23, 21-26 
15-46 0.232 
Other disease location at 
diagnosis 
  L1 
  L2 
  L3 
  No other location 
393 (27.6) 
330 (23.2) 
701 (49.2) 
- 
48 (22.4) 
35 (16.4) 
117 (54.5) 
14 (6.5) 
0.042 
Other disease location at latest 
follow-up 
  L1 
  L2 
  L3 
  No other location 
416 (33.5) 
443 (35.7) 
382 (30.8) 
- 
63 (30.7) 
37 (18.1) 
64 (31.2) 
41 (20.) 
0.003 
Smoking status at diagnosis 
  Non-Smoker 
  Smoker 
703 (51.2) 
670 (48.8) 
106 (52.5) 
96 (47.5) 0.735 
Smoking status at latest follow-
up 
  Non-smoker 
  Smoker 
964 (68.2) 
449 (31.8) 
146 (68.2) 
68 (31.8) 1.000 
NSAID intake at CD onset 
  No 
  Yes 
932 (82.8) 
193 (17.2) 
144 (82.3) 
31 (17.7) 0.856 
Family history of IBD 
  No 
  Yes 
1092 (85.1) 
192 (14.9) 
158 (83.2) 
32 (16.8) 0.498 
Disease behavior 
  B1 743 (52.2) 109 (50.9) 
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  B2 
  B3 
452 (31.7) 
229 (16.1) 
72 (33.7) 
33 (15.4) 0.854 
Perianal disease 
  No 
  Yes 
913 (64.1) 
511 (35.9) 
139 (65.0) 
75 (35.0) 0.812 
Surgical history 
  Intestinal resection 
  Fistula/Abscess surgery 
  Any surgery 
574 (40.3) 
345 (24.2) 
716 (50.3) 
91 (42.5) 
54 (25.2) 
110 (51.4) 
0.539 
0.749 
0.760 
EIM history 
  No 
  Yes 
  Arthritis/Arthralgia 
  Uveitis/Iritis 
  Pyoderma gangrenosum 
  Erythema nodosum 
  Aphtous/oral ulcers 
  Ankylosing spondylitis 
  PSC 
646 (45.4) 
778 (54.6) 
676 (47.5) 
150 (10.5) 
22 (1.5) 
95 (6.7) 
174 (12.2) 
108 (7.6) 
8 (0.6) 
85 (39.7) 
129 (60.3) 
109 (50.9) 
18 (8.4) 
2 (0.9) 
25 (11.7) 
43 (20.1) 
11 (5.1) 
1 (0.5) 
0.121 
0.344 
0.340 
0.760 
0.009 
0.002 
0.199 
1.000 
Medication history 
5-ASA
Antibiotics
Steroids
Immunomodulators
Anti-TNF agents
Calcineurin inhibitors
833 (58.5) 
234 (16.4) 
1225 (86.0) 
1153 (81.0) 
862 (60.5) 
24 (1.7) 
104 (48.6) 
45 (21.0) 
194 (90.7) 
178 (83.2) 
156 (72.9) 
4 (1.9) 
0.006 
0.095 
0.064 
0.440 
0.001 
0.778 
Table 2:  Patient demographic and disease characteristics of CD patients with upper GI tract 
involvement at any time versus control CD patients without such involvement of the proximal GI 
tract. 
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Table 3 
Outcome: Upper GI 
involvement at diagnosis 
Univariate Multivariate 
OR (95%CI) p-value OR (95%CI) p-value
Sex 
  Male (ref) 
  Female 
1.000 (-) 
0.619 (0.417-0.921) 0.018 
1.000 (-) 
0.625 (0.418-0.932) 0.021 
Age at diagnosis 
16 or less 
 More than 16 
1.000 (-) 
0.478 (0.283-0.807) 0.006 
1.000 (-) 
0.388 (0.225-0.668) 0.001 
Age at diagnosis 
[per year] 0.988 (0.972 – 1.003) 0.113 
Year of diagnosis 
  1955-1995 (ref) 
  1996-2003 
  2004-2008 
  2009-2016 
1.000 (-) 
0.838 (0.441-1.593) 
1.230 (0.691-2.192) 
2.379 (1.399-4.044) 
0.590 
0.482 
0.001 
1.000 (-) 
0.830 (0.435-1.582) 
1.270 (0.710-2.274) 
2.686 (1.559-4.625) 
0.571 
0.421 
<0.001 
Initial location 
  No ileal involvement (ref) 
  Ileal involvement 
1.000 (-) 
0.797 (0.512-1.241) 0.315 
BMI [kg/m
2
] 
  < 30 
  ≥ 30 
1.000 (-) 
0.925 (0.485-1.762) 0.812 
Family history of IBD 
  No (ref) 
  Yes 
1.000 (-) 
0.786 (0.422-1.464) 0.448 
Smoking status 
at diagnosis 
  Non-smoker (ref) 
  Smoker 
1.000 (-) 
0.935 (0.625-1.397) 0.742 
Diagnostic delay 
[per month] 1.003 (0.999-1.006) 0.128 
Table 3: Univariate and multivariate logistic regression model for prediction of upper GI tract 
involvement at the time of CD diagnosis. 
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Table 4 
Outcome: Upper GI 
involvement at any time 
Univariate Multivariate 
OR (95%CI) p-value OR (95%CI) p-value
Sex 
  Male (ref) 
  Female 
1.000 (-) 
0.624 (0.467-0.834) 0.001 
1.000 (-) 
0.562 (0.415-0.761) <0.001 
Age at diagnosis 
 16 or less 
 More than 16 
1.000 (-) 
0.547 (0.362-0.826) 0.004 
1.000 (-) 
0.585 (0.382-0.897) 0.014 
Initial location 
  No ileal involvement (ref) 
  Ileal involvement 
1.000 (-) 
1.016 (0.722-1.430) 0.929 
BMI 
  < 30 
  ≥ 30 
1.000 (-) 
0.733 (0.440-1.222) 0.234 
Disease duration 
[per year] 0.984 (0.970-0.999) 0.037 0.981 (0.966-0.996) 0.016 
Family history of IBD 
  No (ref) 
  Yes 
1.000 (-) 
1.152 (0.765-1.735) 0.499 
Smoking status 
at diagnosis 
  Non-smoker (ref) 
  Smoker 
1.000 (-) 
0.950 (0.707-1.277) 0.735 
Appendectomy history 
  No (ref) 
  Yes 
1.000 (-) 
0.617 (0.350-1.090) 0.096 
1.000 (-) 
0.648 (0.364-1.152) 0.139 
EIM history 
  No (ref) 
  Yes 
1.000 (-) 
1.260 (0.940-1.689) 0.122 
EIM history 
  Arthritis/Arthralgia 
  Uveitis/Iritis 
  Pyoderma gangrenosum 
  Erythema nodosum 
  Aphtous/Oral ulcers 
  Ankylosing spondylitis 
  PSC 
1.149 (0.862-1.531) 
0.780 (0.468-1.301) 
0.601 (0.140-2.575) 
1.850 (1.161-2.949) 
1.806 (1.248-2.615) 
0.660 (0.649-1.249) 
0.831 (0.103-6.677) 
0.345 
0.341 
0.493 
0.010 
0.002 
0.202 
0.862 
1.793 (1.100-2.982) 
1.838 (1.249-2.705) 
0.019 
0.002 
CD-related surgery
No (ref)
Yes
1.000 (-) 
1.046 (0.785-1.394) 0.760 
Behaviour 
  B1 (ref) 
  B2 
  B3 
1.000 (-) 
1.085 (0.789-1.495) 
0.982 (0.648-1.490) 
0.614 
0.933 
Perianal disease 
  No (ref) 
  Yes 
1.000 (-) 
0.964 (0.713-1.303) 0.812 
Immunomodulator 
  No (ref) 
  Yes 
1.000 (-) 
1.162 (0.793-1.702) 0.441 
Anti-TNF 
Ac
ce
pte
d M
an
us
cri
pt
  No (ref) 
  Yes 
1.000 (-) 
1.754 (1.274-2.414) 0.001 
1.000 (-) 
1.534 (1.106-2.127) 0.010 
Table 4: Univariate and multivariate logistic regression model for prediction of upper GI tract 
involvement at any time. 
Table 5 
HR (95% CI) p-value
Stenosis 1.063 (0.445 – 2.540) p=0.758 
Perianal Fistula 0.988 (0.399 – 2.448) p=0.955 
Intestinal Fistula 0.418 (0.064 – 3.046) p=0.369 
Any Fistula 0.783 (0.325 – 1.892) p=0.228 
Resection Surgery 0.945 (0.427 – 2.090) p=0.730 
Fistula/Abscess Surgery 0.902 (0.323 – 2.517) p=0.708 
Any Complication 0.887 (0.409 – 1.920) p=0.438 
Table 5: Hazard ratios for development of complications in patients with upper GI tract 
involvement at the time of CD diagnosis compared to controls. 
